TCGA-LL-A5YO-01A-21R-A28M-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 15
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.600
- INTERFERON_GAMMA_RESPONSE+0.500
- INTERFERON_ALPHA_RESPONSE+0.470
- IL6_JAK_STAT3_SIGNALING+0.410
- INFLAMMATORY_RESPONSE+0.390
- COMPLEMENT+0.360
- OXIDATIVE_PHOSPHORYLATION+0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.290
- IL2_STAT5_SIGNALING+0.260
- XENOBIOTIC_METABOLISM+0.240
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.450
- PROTEIN_SECRETION-0.450
- TGF_BETA_SIGNALING-0.450
- UV_RESPONSE_DN-0.420
- MITOTIC_SPINDLE-0.330
- ANGIOGENESIS-0.280
- ESTROGEN_RESPONSE_LATE-0.280
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.270
- NOTCH_SIGNALING-0.250
- HYPOXIA-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E2-A1B6-01A-31R-A12P-07 | — | D | 0.878 |
| 2 | TCGA-EW-A1IZ-01A-11R-A13Q-07 | — | D | 0.855 |
| 3 | TCGA-EW-A1PB-01A-11R-A144-07 | — | E | 0.855 |
| 4 | SRR8392897 | — | cohortSQ2 | 0.842 |
| 5 | SRR9879287 | — | cohortA1 | 0.837 |
| 6 | TCGA-EW-A6SB-01A-12R-A32P-07 | — | E | 0.831 |
| 7 | TCGA-A2-A04X-01A-21R-A034-07 | — | C | 0.829 |
| 8 | TCGA-AC-A6IW-01A-12R-A33J-07 | — | E | 0.826 |
| 9 | 20030081.TNBC | — | D | 0.822 |
| 10 | SRR25617828 | — | D | 0.821 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.600 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.410 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| COMPLEMENT | 0.360 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.290 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.260 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.240 | Inavolisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.190 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| UV_RESPONSE_UP | 0.160 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.140 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.110 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.100 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.080 | Remibrutinib | — uncovered |